RegCell has raised $66.0M in Series A funding, the company confirmed, as it works to bring a more precise class of immune-regulating cells to the clinic.
The company is developing stable, functional-induced Tregs that are antigen-specific, or S/F-iTregs, based on research by founder Professor Shimon Sakaguchi. RegCell says the approach addresses the limitations of earlier attempts to create therapeutic Tregs and offers competitive advantages over CAR-Treg approaches.


















